UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Explore withdrawal approaches for portfolios with SP 500 and Total Stock Market funds to sustain income and minimize risk.
28,406 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
This article outlines why rental properties can redefine how the average American builds wealth. It offers actionable...
Salesforce enters its earnings print amid a mood swing for cloud software, with AI investments weighing on profits an...
Is Rivian a millionaire-maker stock or a high-risk punt? This guide dives into the catalysts, margins, and scenarios ...
SpaceX surged on its IPO buzz, then cooled as investors weighed the risk and reward. This guide breaks down what a 30...
A bold investment thesis hinges on the AI inference niche. After June 3, the market could reward execution as much as...
A tectonic shift is quietly unfolding in mobility and AI. The trillion robotaxi boom real could power a new era of ea...
Nvidia sits at a pivotal crossroads as driverless technology could next reshape how auto tech and AI collide. This ar...
Palantir sits at the intersection of AI hype and durable analytics. This guide unpacks does palantir's valuation make...
In the first half of 2026, Vertiv soared as AI data centers pushed demand for cooling and power solutions. This artic...
A niche AI hardware stock is drawing investors as hyperscale data centers surge. Analysts say this stock could easies...
Explore Innoviz's path in 2026 with a deep dive into Q1 results, margins, backlog, and strategic bets. This analysis ...